/MicroRNA-34 Axis in Cancer and Beyond

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Apr 25

PMID 37095919

Authors

Wei Pan

Binshu Chai

Langping Li

Zhijun Lu

Zhongliang Ma

Affiliations

Soon will be listed here.

Abstract

Cancer is serious endangers human life. After a long period of research and accumulation, people's understanding of cancer and the corresponding treatment methods are constantly developing. is an important tumor suppressor gene. With the more in-depth understanding of the structure and function of , the more importance of this tumor suppressor gene is realized in the process of inhibiting tumor formation. MicroRNAs (miRNAs) are important regulatory molecules with a length of about 22nucleotides (nt), which belong to non-coding RNA and play an important role in the occurrence and development of tumors. miR-34 is currently considered to be a master regulator of tumor suppression. The positive feedback regulatory network formed by and miR-34 can inhibit the growth and metastasis of tumor cells and inhibit tumor stem cells. This review focuses on the latest progress of 3/miR-34 regulatory network, and discusses its application in tumor diagnosis and treatment.

Citing Articles

Regulates Muscle Growth and Development by Targeting .

Wu Y, Liu X, Fan Y, Zuo H, Niu X, Zuo B Cells. 2025; 14(5).

PMID: 40072107 PMC: 11898696. DOI: 10.3390/cells14050379.

Novel Detection and Clinical Utility of Serum-Derived Extracellular Vesicle in Angiosarcoma.

Yokoi K, Wang J, Yoshioka Y, Fujisawa Y, Fujimoto M, Ochiya T Acta Derm Venereol. 2025; 105:adv40902.

PMID: 40001341 PMC: 11877856. DOI: 10.2340/actadv.v105.40902.

A Critical Review on microRNAs as Prognostic Biomarkers in Laryngeal Carcinoma.

Komitova K, Dimitrov L, Stancheva G, Kyurkchiyan S, Petkova V, Dimitrov S Int J Mol Sci. 2025; 25(24.

PMID: 39769234 PMC: 11676902. DOI: 10.3390/ijms252413468.

Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155.

Qian H, Maghsoudloo M, Jabbarzadeh Kaboli P, Babaeizad A, Cui Y, Fu J Int J Med Sci. 2024; 21(14):2781-2798.

PMID: 39512697 PMC: 11539376. DOI: 10.7150/ijms.102123.

The role of p53 in male infertility.

Li J, Huang X, Luo L, Sun J, Guo Q, Yang X Front Endocrinol (Lausanne). 2024; 15:1457985.

PMID: 39469578 PMC: 11513281. DOI: 10.3389/fendo.2024.1457985.

References

Jansson K, Tucker J, Stahl L, Simmons J, Fuller C, Beshiri M . High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Sci Rep. 2018; 8(1):17239. PMC: 6250716. DOI: 10.1038/s41598-018-35417-0. View

Akbar R, Ullah K, Ur Rahman T, Cheng Y, Pang H, Jin L . miR-183-5p regulates uterine receptivity and enhances embryo implantation. J Mol Endocrinol. 2019; 64(1):43-52. DOI: 10.1530/JME-19-0184. View

Lam-Ubol A, Fitzgerald A, Ritdej A, Phonyiam T, Zhang H, Myers J . Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo. Food Funct. 2018; 9(7):3640-3656. DOI: 10.1039/c8fo00865e. View

Shree B, Sengar S, Tripathi S, Sharma V . LINC01711 promotes transforming growth factor-beta (TGF-β) induced invasion in glioblastoma multiforme (GBM) by acting as a competing endogenous RNA for miR-34a and promoting ZEB1 expression. Neurosci Lett. 2022; 792:136937. DOI: 10.1016/j.neulet.2022.136937. View

Li F, Li X, Qiao L, Liu W, Xu C, Wang X . MALAT1 regulates miR-34a expression in melanoma cells. Cell Death Dis. 2019; 10(6):389. PMC: 6525244. DOI: 10.1038/s41419-019-1620-3. View

Rokavec M, Oner M, Li H, Jackstadt R, Jiang L, Lodygin D . Corrigendum. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2015; 125(3):1362. PMC: 4362232. DOI: 10.1172/JCI81340. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Alshehri A, El-Kott A, El-Kenawy A, Khalifa H, AlRamlawy A . Cadmium chloride induces non-alcoholic fatty liver disease in rats by stimulating miR-34a/SIRT1/FXR/p53 axis. Sci Total Environ. 2021; 784:147182. DOI: 10.1016/j.scitotenv.2021.147182. View

Chen D, Chu B, Yang X, Liu Z, Jin Y, Kon N . iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat Commun. 2021; 12(1):3644. PMC: 8206155. DOI: 10.1038/s41467-021-23902-6. View

10.

Zhai L, Zhao Y, Liu Z, Wu J, Lin L . mRNA expression profile analysis reveals a C-MYC/miR-34a pathway involved in the apoptosis of diffuse large B-cell lymphoma cells induced by Yiqichutan treatment. Exp Ther Med. 2020; 20(3):2157-2165. PMC: 7401774. DOI: 10.3892/etm.2020.8940. View

11.

Pi C, Ma C, Wang H, Sun H, Yu X, Gao X . MiR-34a suppression targets Nampt to ameliorate bone marrow mesenchymal stem cell senescence by regulating NAD-Sirt1 pathway. Stem Cell Res Ther. 2021; 12(1):271. PMC: 8101138. DOI: 10.1186/s13287-021-02339-0. View

12.

Gatsiou A, Georgiopoulos G, Vlachogiannis N, Pfisterer L, Fischer A, Sachse M . Additive contribution of microRNA-34a/b/c to human arterial ageing and atherosclerosis. Atherosclerosis. 2021; 327:49-58. DOI: 10.1016/j.atherosclerosis.2021.05.005. View

13.

Chen Y, Liu X, Li L . Prognostic value of low microRNA-34a expression in human gastrointestinal cancer: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1):63. PMC: 7807881. DOI: 10.1186/s12885-020-07751-y. View

14.

Bazrgar M, Khodabakhsh P, Prudencio M, Mohagheghi F, Ahmadiani A . The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders. Pharmacol Res. 2021; 172:105805. DOI: 10.1016/j.phrs.2021.105805. View

15.

Zhang L, Wang L, Dong D, Wang Z, Ji W, Yu M . MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Cell Prolif. 2018; 52(1):e12527. PMC: 6430481. DOI: 10.1111/cpr.12527. View

16.

Deng S, Wang M, Wang C, Zeng Y, Qin X, Tan Y . p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target. Mol Biol Rep. 2022; 50(1):577-587. DOI: 10.1007/s11033-022-08047-z. View

17.

Ou Y, Wang S, Li D, Chu B, Gu W . Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A. 2016; 113(44):E6806-E6812. PMC: 5098629. DOI: 10.1073/pnas.1607152113. View

18.

Taylor A, Lee D, Allard M, Poland B, Slatter J . Phase 1 Concentration-QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT-232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia. Clin Pharmacol Drug Dev. 2021; 10(8):918-926. PMC: 8451834. DOI: 10.1002/cpdd.903. View

19.

Steele T, Talbott G, Sam A, Tepper C, Ghosh P, Vinall R . Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. Int J Mol Sci. 2019; 20(6). PMC: 6470498. DOI: 10.3390/ijms20061285. View

20.

Amirtharaj F, Venkatesh G, Wojtas B, Nawafleh H, Mahmood A, Nizami Z . p53 reactivating small molecule PRIMA‑1/APR‑246 regulates genomic instability in MDA‑MB‑231 cells. Oncol Rep. 2022; 47(4). DOI: 10.3892/or.2022.8296. View